The HSP90 inhibitor 17-N-allylamino-17-demethoxy geldanamycin
The HSP90 inhibitor 17-N-allylamino-17-demethoxy geldanamycin
About this item
Full title
The HSP90 inhibitor 17-N-allylamino-17-demethoxy geldanamycin
Author / Creator
Publisher
Spandidos Publications
Journal title
Oncology reports, 2014-02, Vol.31 (2), p.619
Language
English
Formats
Publication information
Publisher
Spandidos Publications
Subjects
More information
Scope and Contents
Contents
Although cisplatin (CDDP) is a key drug in the treatment of esophageal squamous cell carcinoma (ESCC), acquired chemoresistance remains a major problem. Combination therapy may represent one strategy to overcome this resistance. Heat shock protein 90 (HSP90) is known to be overexpressed in several types of cancer cells, and its inhibition by small...
Alternative Titles
Full title
The HSP90 inhibitor 17-N-allylamino-17-demethoxy geldanamycin
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_gale_healthsolutions_A415562911
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_gale_healthsolutions_A415562911
Other Identifiers
ISSN
1021-335X
How to access this item
Log in as a Library member
